Blog
RSS FeedPosted by Michael Wonder on 05 Jun 2024
ICER publishes protocol for annual assessment of drug coverage policies that present barriers to fair access
5 June 2024 - This year’s analysis will include the top ten commercial formularies by covered lives, and include drugs ...
Posted by Michael Wonder on 28 May 2024
The impact of proposed price regulations on new patented medicine launches in Canada: a retrospective cohort study
27 May 2024 - The Patented Medicine Prices Review Board (PMPRB), the agency that regulates the prices of patented medicines in ...
Posted by Michael Wonder on 23 May 2024
PMPRB report examines availability and pricing of new medicines
22 May 2024 - The Patented Medicine Prices Review Board (PMPRB) published the eighth edition of its annual Meds Entry Watch ...
Posted by Michael Wonder on 01 May 2024
'What is the price of comfort?': Oncologist raises concerns about newly approved cancer treatment in Canada
30 April 2024 - A new cancer treatment recently approved in Canada promises to cut treatment time down to just ...
Posted by Michael Wonder on 30 Apr 2024
J&J, BMS lose challenges to US drug price negotiation program
29 April 2024 - A US judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson ...
Posted by Michael Wonder on 23 Apr 2024
ICER and NEWDIGS release white paper analysing the challenges and potential policy options for paying for gene therapies
23 April 2024 - Paper outlines policy reforms and market actions to support innovation and access while managing uncertainty, affordability, ...
Posted by Michael Wonder on 14 Apr 2024
Cost based pricing for innovative medicines Is unviable and harmful
12 April 2024 - Barber et al. just published a fundamentally flawed study on diabetes medicines in JAMA Network Open. ...
Posted by Michael Wonder on 12 Apr 2024
Medicare drug price negotiations: policy implications of the first 10 drugs’ features
9 April 2024 - This article describes how CMS’s approach to implementing the negotiations will be shaped by the distinctive ...
Posted by Michael Wonder on 09 Apr 2024
ICER publishes 2024 research protocol for assessing unsupported price increases on prescription drugs
9 April 2024 - Input period now open until 13 May 2024. ...
Posted by Michael Wonder on 05 Apr 2024
Net prices for medicines fell considerably in 2023’s last quarter, mostly thanks to Humira biosimilars
1 April 2024 - The net prices that health plans paid for medicines — after subtracting rebates, discounts, and fees ...
Posted by Michael Wonder on 02 Apr 2024
Joe Biden’s assault on the $900 child eczema cream
2 April 2024 - What the Inflation Reduction Act means for the cost of health care. ...
Posted by Michael Wonder on 21 Mar 2024
AstraZeneca caps patient out of pocket costs at $35 per month for its US inhaled respiratory portfolio
18 March 2024 - Expanded savings programs build on company’s longstanding commitment to addressing barriers to access and affordability for ...
Posted by Michael Wonder on 08 Mar 2024
Boehringer Ingelheim caps patient out of pocket costs for its inhaler portfolio at $35 per month
7 March 2024 - Boehringer makes significant investment to improve the affordability of and access to its full range of inhaler ...
Posted by Michael Wonder on 07 Mar 2024
Biden says Medicare should negotiate prices for at least 50 drugs each year, up from a target of 20
6 March 2024 - That proposal is one of several new health care policy plans Biden will outline during his State ...
Posted by Michael Wonder on 07 Mar 2024
Early impact of the Inflation Reduction Act on drug discovery
6 March 2024 - Despite the concerns of the biopharma industry, the Inflation Reduction Act has been enacted and with it, ...